Analysts Set Aclaris Therapeutics Inc (ACRS) Price Target at $44.50

Aclaris Therapeutics Inc (NASDAQ:ACRS) has been given an average rating of “Hold” by the seven research firms that are presently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a sell rating and four have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $44.50.

Several research analysts have issued reports on ACRS shares. BidaskClub cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, December 20th. Cantor Fitzgerald set a $50.00 price target on Aclaris Therapeutics and gave the company a “buy” rating in a research report on Friday, December 15th. Guggenheim assumed coverage on Aclaris Therapeutics in a research report on Thursday, February 8th. They issued a “buy” rating and a $53.00 price target for the company. Finally, Zacks Investment Research cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd.

Several hedge funds have recently made changes to their positions in ACRS. Schwab Charles Investment Management Inc. increased its position in shares of Aclaris Therapeutics by 40.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 61,765 shares of the biotechnology company’s stock valued at $1,676,000 after buying an additional 17,804 shares in the last quarter. Legal & General Group Plc increased its position in shares of Aclaris Therapeutics by 98.3% in the second quarter. Legal & General Group Plc now owns 5,254 shares of the biotechnology company’s stock valued at $142,000 after buying an additional 2,605 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Aclaris Therapeutics by 230.8% in the second quarter. Wells Fargo & Company MN now owns 40,883 shares of the biotechnology company’s stock valued at $1,109,000 after buying an additional 28,524 shares in the last quarter. Alliancebernstein L.P. increased its position in shares of Aclaris Therapeutics by 109.7% in the second quarter. Alliancebernstein L.P. now owns 19,500 shares of the biotechnology company’s stock valued at $529,000 after buying an additional 10,200 shares in the last quarter. Finally, Teachers Advisors LLC increased its position in shares of Aclaris Therapeutics by 84.0% in the second quarter. Teachers Advisors LLC now owns 36,751 shares of the biotechnology company’s stock valued at $997,000 after buying an additional 16,783 shares in the last quarter. Institutional investors and hedge funds own 92.47% of the company’s stock.

Aclaris Therapeutics (ACRS) traded up $0.66 during trading hours on Tuesday, reaching $20.22. The company’s stock had a trading volume of 220,500 shares, compared to its average volume of 356,105. The stock has a market capitalization of $603.13, a PE ratio of -9.36 and a beta of 1.26. Aclaris Therapeutics has a 1 year low of $18.46 and a 1 year high of $33.25.

TRADEMARK VIOLATION WARNING: This piece was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://stocknewstimes.com/2018/02/16/analysts-set-aclaris-therapeutics-inc-acrs-price-target-at-44-50.html.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply